Cancer drugs

From Libre Pathology
Revision as of 02:45, 15 August 2011 by Michael (talk | contribs) (create)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

This article covers cancer drugs from a pathology perspective.

Drugs in a table

Non-proprietary name Trade name Cost Indication Notes
cetuximab Erbitux 5267 Euros/month[1] stomach cancer, head & neck cancer notes?
trastuzumab Herceptin 3345 Euros/month[1] breast cancer, stomach cancer notes?
non-proprietary name Iressa 3496 Euros/month[1] Lung cancer notes?
panitumumab Vectibix 3537 Euros/month[1] indication notes?
non-proprietary name Faslodex 719 Euros/month[1] breast cancer notes?
non-proprietary name Femara 4189 Euros/month[1] indication notes?
non-proprietary name Glivec 4189 Euros/month[1] ALL, CML notes?
non-proprietary name Sprycel 7513 Euros/month[1] ALL, CML notes?
non-proprietary name Tasigna 5685 Euros/month[1] CML notes?
non-proprietary name Tyverb 3441 Euros/month[1] breast cancer notes?

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Grill, Markus; Hackenbroch, Veronika (2011), "[Medizin: Das grosse Versprechen]", Der Spiegel (32): 124-128, 8.8.2011
Retrieved from "https://librepathology.org/w/index.php?title=Cancer_drugs&oldid=6629"